Guggenheim Maintains Buy on Dianthus Therapeutics, Raises Price Target to $200
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Yatin Suneja maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $100 to $200.
Guggenheim analyst Yatin Suneja maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $100 to $200.